Little is known about the characteristics and treatments of patients with severe asthma across Europe, but both are likely to vary. This is the first study in the European Respiratory Society Severe Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) Clinical Research Collaboration and it is designed to explore these variations. Therefore, we aimed to compare characteristics of patients in European severe asthma registries and treatments before starting biologicals. This was a cross-sectional retrospective analysis of aggregated data from 11 national severe asthma registries that joined SHARP with established patient databases. Analysis of data from 3236 patients showed many differences in characteristics and lifestyle factors. Current smokers ranged from 0% (Poland and Sweden) to 9.5% (Belgium), mean body mass index ranged from 26.2 (Italy) to 30.6 kg·m−2 (the UK) and the largest difference in mean pre-bronchodilator forced expiratory volume in 1 s % predicted was 20.9% (the Netherlands versus Hungary). Before starting biologicals patients were treated differently between countries: mean inhaled corticosteroid dose ranged from 700 to 1335 µg·day−1 between those from Slovenia versus Poland when starting anti-interleukin (IL)-5 antibody and from 772 to 1344 µg·day−1 in those starting anti-IgE (Slovenia versus Spain). Maintenance oral corticosteroid use ranged from 21.0% (Belgium) to 63.0% (Sweden) and from 9.1% (Denmark) to 56.1% (the UK) in patients starting anti-IL-5 and anti-IgE, respectively. The severe asthmatic population in Europe is heterogeneous and differs in both clinical characteristics and treatment, often appearing not to comply with the current European Respiratory Society/American Thoracic Society guidelines definition of severe asthma. Treatment regimens before starting biologicals were different from inclusion criteria in clinical trials and varied between countries. The severe asthma population in Europe is heterogeneous and differs in clinical characteristics and treatment. Harmonisation across registries and guidelines is needed and requires collection of same data across cohorts to enable future research in SHARP. http://bit.ly/2krxHPf

中文翻译：

---

ERS SHARP 严重哮喘登记处的特征和治疗方案

人们对欧洲严重哮喘患者的特征和治疗方法知之甚少，但两者可能各不相同。这是欧洲呼吸学会严重异质性哮喘研究合作、以患者为中心 (SHARP) 临床研究合作的第一项研究，旨在探索这些变化。因此，我们旨在在开始生物制剂之前比较欧洲严重哮喘登记处和治疗中患者的特征。这是对 11 个国家严重哮喘登记处汇总数据的横断面回顾性分析，这些登记处加入了 SHARP 并建立了患者数据库。对 3236 名患者的数据分析显示，在特征和生活方式因素方面存在许多差异。目前吸烟者的范围从 0%（波兰和瑞典）到 9.5%（比利时），平均体重指数范围从 26.2（意大利）到 30.6 kg·m-2（英国），并且在 1 s % 预测值内，支气管扩张剂前平均用力呼气量的最大差异为 20.9%（荷兰与匈牙利）。在开始使用生物制剂之前，各国对患者的治疗不同：斯洛文尼亚和波兰的患者在开始使用抗白细胞介素 (IL)-5 抗体时平均吸入皮质类固醇剂量范围为 700 至 1335 µg·day−1，而在 772 到 1344 µg·day−之间在那些开始抗 IgE 的人群中排名第一（斯洛文尼亚对西班牙）。在开始抗 IL-5 和抗 IgE 的患者中，维持口服皮质类固醇的使用范围分别为 21.0%（比利时）至 63.0%（瑞典）和 9.1%（丹麦）至 56.1%（英国）。欧洲的重度哮喘人群具有异质性，临床特征和治疗方法各不相同，通常似乎不符合当前欧洲呼吸学会/美国胸科学会指南对严重哮喘的定义。开始生物制剂之前的治疗方案与临床试验中的纳入标准不同，各国之间也有所不同。欧洲的重度哮喘人群具有异质性，临床特征和治疗各不相同。需要在注册和指南之间进行协调，并且需要跨队列收集相同的数据，以支持 SHARP 的未来研究。http://bit.ly/2krxHPf 欧洲的重度哮喘人群具有异质性，临床特征和治疗各不相同。需要在注册和指南之间进行协调，并且需要跨队列收集相同的数据，以支持 SHARP 的未来研究。http://bit.ly/2krxHPf 欧洲的重度哮喘人群具有异质性，临床特征和治疗各不相同。需要在注册和指南之间进行协调，并且需要跨队列收集相同的数据，以支持 SHARP 的未来研究。http://bit.ly/2krxHPf